We sought to examined the utility of quantification of cerebrospinal fluid (CSF) α-synouclein (α-syn) in differentiate patients with Parkinson disease (PD), multiple system atrophy (MSA) and healthy controls, after strict control of confounder variables such as RBCs in CSF.
